Q3 Earnings Forecast for NeuroPace Issued By HC Wainwright

NeuroPace, Inc. (NASDAQ:NPCE) – Investment analysts at HC Wainwright reduced their Q3 2027 earnings estimates for NeuroPace in a research report issued to clients and investors on Thursday, August 13th. HC Wainwright analyst Y. Chen now forecasts that the company will earn $0.05 per share for the quarter, down from their previous forecast of $0.06. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for NeuroPace’s current full-year earnings is ($0.54) per share. HC Wainwright also issued estimates for NeuroPace’s Q4 2027 earnings at $0.11 EPS and FY2027 earnings at $0.09 EPS.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.04. NeuroPace had a negative net margin of 19.34% and a negative return on equity of 105.64%. The firm had revenue of $22.83 million during the quarter, compared to the consensus estimate of $22.61 million.

A number of other analysts have also commented on NPCE. Guggenheim reaffirmed a “neutral” rating on shares of NeuroPace in a research report on Wednesday, July 29th. Mizuho started coverage on NeuroPace in a report on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroPace in a research note on Wednesday, June 24th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of NeuroPace in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.29.

NeuroPace Price Performance

NPCE stock opened at $14.64 on Thursday. The company has a debt-to-equity ratio of 4.97, a current ratio of 4.94 and a quick ratio of 3.91. The company’s 50-day moving average is $15.40 and its 200-day moving average is $15.34. The stock has a market capitalization of $502.44 million, a PE ratio of -25.68 and a beta of 1.92. NeuroPace has a 1 year low of $8.17 and a 1 year high of $19.60.

Institutional Investors Weigh In On NeuroPace

Several hedge funds and other institutional investors have recently made changes to their positions in the business. First Light Asset Management LLC lifted its position in NeuroPace by 82.3% in the 1st quarter. First Light Asset Management LLC now owns 2,459,966 shares of the company’s stock valued at $32,349,000 after acquiring an additional 1,110,484 shares in the last quarter. GSA Capital Partners LLP bought a new stake in NeuroPace during the 2nd quarter worth approximately $1,836,000. Sei Investments Co. raised its stake in shares of NeuroPace by 51.4% in the first quarter. Sei Investments Co. now owns 121,476 shares of the company’s stock worth $1,597,000 after purchasing an additional 41,233 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of NeuroPace in the second quarter worth approximately $35,000. Finally, Legal & General Group Plc lifted its holdings in shares of NeuroPace by 86.0% in the second quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock valued at $30,000 after purchasing an additional 1,239 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

About NeuroPace

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.